Mediar Therapeutics
Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and
progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Live
Website
www.mediartx.com
Related News
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)
Mediar Therapeutics initiates second clinical program in portfolio of novel first-in-class antibodies designed to halt fibrosis
Mediar advances first-in-class fibrosis portfolio to the clinic with first cohort dosing in Phase 1 trial of MTX-463 and establishes clinical advisory board
Mediar Therapeutics announces clinical candidates for lead fibrosis programs, strategic collaborations and key leadership addition
Mediar Therapeutics announces $105 million financing to advance portfolio of first-in-class fibrosis therapies
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.